Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device

NCT ID: NCT04841629

Last Updated: 2022-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-24

Study Completion Date

2022-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applicator design will be evaluated for: look and feel, ability to prepare for dosing, ability to expulse dose, and likelihood of future use by subjects. Open-ended feedback on the gel and applicator will occur to gather contributions for each product.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is being conducted as a component of a NIH/NCI sponsored Small Business Technology Transfer (STTR) project entitled "Cervical Cancer Prevention Prebiotic Device."

The prebiotic vaginal gel, PreBioGyn, has been developed to optimize vaginal health and reduce the risk of cervical cancer in women. Use of the gel targets a combination of biological risk factors for cervical cancer including restoring and maintaining healthy vaginal microbiota, pH, and mucosal function, thereby preventing disturbed immunity and inflammation caused by dysbiosis and mucosal microtrauma. The purpose of this study is to provide a quantitative perception evaluation of the acceptability of PreBioGyn and its applicator system.

The objectives of this study are to:

1. Perform a quantitative sensory evaluation to determine the topical acceptability of PreBioGyn, as well as receive qualitative feedback on the gel, as compared to competitive products.
2. Obtain quantitative and qualitative feedback regarding acceptability of the PreBioGyn applicator compared to those for existing competitive products.

These Study Objectives do not involve actual intravaginal use of the product. Rather, this activity will involve presentation of the products in a forearm and finger-touch sensory evaluation, and the answering of questions related to this perceptual evaluation.

Study Design:

This is a randomized, single-blind, cross-over study that will include 42 women.

Study Procedures and Methods:

Quantitative sensory evaluation and qualitative feedback to determine the acceptability of the prebiotic vaginal gel (PreBioGyn) as compared to competitive products

Summary:

Quantitative evaluation of PreBioGyn and two competitive vaginal pH buffer-gels will be performed. The four key qualitative parameters to be evaluated are slipperiness, tackiness, appearance, and smell. These parameters are key functional outcomes for the final PreBioGyn formula. Qualitative feedback and likelihood of use for each gel will also be collected and scored.

1. Quantitative Assessment of Slipperiness and Tackiness ("lubricity").

Quantitative perceptual lubricity (slipperiness and tackiness) will be determined using a standardized methodology wherein participants discriminate differences between the PreBioGyn and two competitive products, versus positive and negative anchor products. Products are evaluated on the skin (forearm area) ex vivo.

Participants will each receive the positive and negative anchors, then the three gel products, on three different 4-cm circular forearm sites. The order of the gels, and the circle to which it was applied, will be determined randomly based on a computer-generated randomization table. Each treatment is replicated twice. Participants will be blinded to the specific products used.

Fingers and circles will be wiped with a low-residue baby-wipe and paper towel. The investigator dispenses 0.2 ml of the sample into the center of the circle previously drawn on the forearm. The sample is rubbed in a circle using the index finger at a rate of 2 revolutions per second for 15 seconds and followed with another 45 seconds (60 second time point). A metronome is set at 120 bpm and played to standardize the manipulation rate.

At time points 15 and 60 seconds, slipperiness is evaluated using a visual analog scale (VAS). The two ends of the visual analog scale are anchored by the phrases "not slippery" and "very slippery." The participant is asked to make a mark on the VAS at the point of their slipperiness assessment between the two anchors. Prior to study gel measurements, participants will perform evaluations on two products representing the negative anchor "not slippery" (lanolin) and positive anchor "very slippery" (Gun Oilâ„¢ lubricant).

At the 60-second time point, and after the slipperiness score is recorded, subjects will assess tackiness by tapping their finger up and down for 5 seconds on the skin in the circle just used to assess slipperiness.

Tackiness is evaluated using the visual analog scale. The two ends of the visual analog scale are anchored by the phrases "Not tacky or sticky" and "very tacky or sticky." The focus group participant is asked to make a mark on the VAS at the point of their tackiness assessment between the two anchors. Prior to study gel measurements, participants will perform evaluations on two products representing the anchors of "very tacky" (lanolin) and "not tacky" (Gun Oil® lubricant). The degree of slipperiness and tackiness is determined by measuring the distance of the participants mark on the visual analog scale from the left baseline.
2. Qualitative Assessment of Appearance and Smell and Overall Perception.

Study participants will be asked to rate the appearance and smell of the PreBioGyn and competitive products following the end of the quantitative assessment period. The traditional nine-point hedonic scale will be used to assess the degree of liking or disliking of each gel's smell and appearance. The reliability, validity and discriminative ability of the scale has been proven in food, cosmetic, and personal care product acceptance tests.

Two milliliters (2 ml) of each lubricant will be dispensed from a prefilled syringe onto a small clear plastic petri dish. The order of the gel will be determined randomly based on a computer-generated randomization table. Each treatment is replicated twice. Participants will be blinded to the product identity. Subjects will be asked to observe the gels under good lighting, smell the gels from a distance of approximately 2-5 cm from the end of their nose, and then rate each gel on the Hedonic scale. Finally, open-ended feedback on the gels, including likelihood of use as a proposed product to decrease cervical cancer risk, will occur using the "I Like, I Wish, What If" method to gather participant contributions.
3. Quantitative and Qualitative Feedback Regarding Acceptability of the PreBioGyn Applicator Compared to Competitive Products.

Women will rank the PreBioGyn applicator versus that of competitive products in a 9-point Hedonic scale for acceptability of the applicator look and feel; the usability for preparing the applicator for dosing, and the usability to expel the gel (table-top). Finally, the overall reaction to the concept of inserting each applicator vaginally will be rated, as well as a 5-point Likert-scale rating of likelihood of future use of each product to reduce cervical cancer risk. Finally, open-ended feedback on the applicators will occur using the "I Like, I Wish, What If" method to gather participant contributions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensory Perceptual Characteristics User Acceptability of Gel Delivery System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PreBioGyn Gel

Topical administration to forearm

Group Type EXPERIMENTAL

PreBioGyn Gel

Intervention Type OTHER

Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.

Trimosan Gel

Topical administration to forearm

Group Type ACTIVE_COMPARATOR

Trimosan Gel

Intervention Type OTHER

Carbomer-based gel

RepHresh Gel

Topical administration to forearm

Group Type ACTIVE_COMPARATOR

RepHresh Gel

Intervention Type OTHER

Carbomer-based gel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PreBioGyn Gel

Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.

Intervention Type OTHER

Trimosan Gel

Carbomer-based gel

Intervention Type OTHER

RepHresh Gel

Carbomer-based gel

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* hrHPV positive
* 30 years of age or older
* Have not received the HPV vaccine
* Not pregnant or nursing
* Medicaid eligible

Exclusion Criteria

* history of skin irritation and/or allergic skin reactions
Minimum Eligible Age

30 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brigham and Women's Hospital

OTHER

Sponsor Role collaborator

University of Puerto Rico

OTHER

Sponsor Role collaborator

Glyciome, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joanna Ellington, PhD

Role: PRINCIPAL_INVESTIGATOR

Glyciome, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brigham and Women'S Hospital

Boston, Massachusetts, United States

Site Status

University of Puerto Rico Medical Sciences

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R41CA254543

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gyn Onc Prehab Study
NCT04298827 COMPLETED NA